We had several financings that didnt make the 12/1 edition of Vital Signs. Biolexis Therapeutics – a company using AI for metabolic drug discovery, raised a $10M Series A. (American Fork, UT) Aperiam Bio – a protein engineering company, raised a $9M Seed extension.(Brooklyn, NY) Arrivo Bioventures – a drug developer, raised a $45M Series… Continue reading Financings – Cont. from Vital Signs 12/1/23
When a startup or an investment is successful, it’s more likely that we attribute the outcome to a great idea and solid execution. While these two attributes are critical, they are not sufficient. skill. Over the years, some of our most successful entrepreneurs and investors have shared that luck is underestimated in this equation. Mark… Continue reading Luck
We had several financings that didnt make the 11/14 edition of Vital Signs. VectorY Therapeutics – a biotech company developing antibody therapies to treat neurodegenerative diseases, raised a $138M Series A. (Amsterdam, Netherlands) Needed – a company that develops nutrition products for prenatal care, raised $14M. (LA, CA)
Listings that didn’t get included in the 11/7/23 edition of Vital Signs are here. If you are NOT receiving Vital Signs via email, send us a note and we’ll make sure to get you on the distribution list. The email briefing is designed to keep you informed of financings, new ideas and provide helpful educational… Continue reading Financings – Cont. from Vital Signs 11/7/23
The slow medtech IPO (Initial Public Offering) market in 2023 is having a significant impact on venture capital investments in the medical technology (medtech) sector. For purposes of this post, we include therapeutics and digital health in the broad term “medtech.” According to Evaluate Medtech, there were exactly zero IPOs in the space in the… Continue reading The MedTech IPO Market is Dead
Listings that didn’t get included in the 9/29/23 edition of Vital Signs are here. If you are NOT receiving Vital Signs via email, send us a note and we’ll make sure to get you on the distribution list. The email briefing is designed to keep you informed of financings, new ideas and provide helpful educational… Continue reading Financings – Continued from Vital Signs 9/29/23
Medtech financings continue at a rapid pace led by therapeutics, AI and robotics. Below are just a few of the fundings we couldnt fit into a Vital Signs newsletter. CMR Surgical – a surgical robotics company, raised $165M. (Cambridge, UK) Corti – an AI assistant for healthcare professionals, raised a $60M Series B. (Copenhagen, DN)… Continue reading Medtech Financings
As Fall gets underway, it’s an ideal time for every company to prepare for 2024 strategic planning. (this certainly includes medical practices, but for this post we will focus on startups) Strategic Planning is often pushed under the rug by business owners/operators because they are too busy treading water. We get it. Everyone has the… Continue reading Annual Strategic Planning
A number of years ago, we decided it was important to figure out how to filter startups based on likelihood of success. This seemed like a daunting task because it’s highly speculative. If you ask 5 investors to rate 5 startups you are likely to get 6 different opinions most of the time. Everyone approaches… Continue reading Startup Evaluation – Step 2: Coachability
When veterans of AngelMD hear a startup presentation and receive the startup’s projections, we have learned enough to know that if they get to a successful conclusion, very little will look like the original plan. Startup success always depends on interaction. It’s critical in business-building and so is being able to determine the ability… Continue reading Startup Evaluation – Step 1: Adaptability
AngelMD is a large and growing healthcare innovation community connecting clinicians, startups, investors, Industry and other stakeholders.
AngelMD is a large and growing healthcare innovation community centered around clinician & startups with tools & education for both.
